Search
Altimmune Inc
ALTAdd to Watchlist
2.920USD
+0.220+8.15%
Close 06/22, 16:00（ET）Quotes delayed by 15 min
323.78MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-22The current earnings forecast score of Altimmune Inc is 8.00, ranking 164 out of 389 in the Biotechnology & Medical Research industry. The average price target is 20.00, with a high of 28.00 and a low of 1.00.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
16.850
Target Price
+524.07%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Altimmune Inc
ALT
11
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Altimmune Inc's expected revenue for the next quarter?
Altimmune Inc's expected revenue is 1.75K.
What is Altimmune Inc's price target?
Analysts forecast that Altimmune Inc's price target is USD 20.00, with the highest forecast at USD 28.00 and the lowest forecast at USD 1.00.
How have Altimmune IncALT's recent earnings per share performed?
The market expectation was USD -0.18, while Altimmune IncALT's earnings per share (EPS) for the previous quarter was USD -0.26. EPS for the next quarter is expected at USD -0.16.
What is the analyst rating for Altimmune Inc?
Based on the ratings of Altimmune Inc's stock from 11 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
